Skip to main content

Advertisement

SpringerLink
Log in

Neutrophil-to-lymphocyte ratio predicts PSA response, but not outcomes in patients with castration-resistant prostate cancer treated with docetaxel

  • Urology - Original Paper
  • Published:
International Urology and Nephrology Aims and scope Submit manuscript

Abstract

Purpose

The neutrophil-to-lymphocyte ratio (NLR) is a marker of systemic inflammatory response and evidences for the relationship between NLR and the response to treatment gradually increases in cancer patients. In this study, we aimed to investigate the effect of the pretreatment NLR and other factors related to the patient on predicting the outcome of docetaxel + prednisone chemotherapy in prostate cancer patients who become castration resistant.

Materials and methods

Thirty-three metastatic castration-resistant prostate cancer patients those who were treated between 2009 and 2013 were included in our study. All data of the patients, including pathological, clinical, radiological, biochemical and hematological data, were assessed retrospectively using our database system.

Results

The median progression-free survival (PFS) was determined as 23.9 months (range 0.36–118.7) with androgen suppression therapy and 9.5 months (range 1.7–39.4) with docetaxel + prednisone therapy. NLR was found to be correlated with only posttreatment psa levels. In the NLR ≤3 group, the PSA levels were statistically significantly lower than the other group (r = 0.002). Furthermore, the relationships between the clinical response and PFS and the other pretreatment parameters of the patients were evaluated in order to predict which group would respond better to docetaxel + prednisone therapy after becoming androgen resistant. No relationship was found between any of the parameters and the response to therapy.

Conclusion

Although NLR was found effective in predicting the PSA response in docetaxel + prednisone therapy, neither NLR nor any other clinical parameter was found effective in predicting the outcome and the role of NLR in the future of CRPC is questionable.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Jemal A, Bray F, Center MM et al (2011) Global cancer statistics. CA Cancer J Clin 61:69

    Article  PubMed  Google Scholar 

  2. Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, Oudard S, Theodore C, James ND, Turesson I, Rosenthal MA, Eisenberger MA (2004) Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351:1502–1512

    Article  CAS  PubMed  Google Scholar 

  3. Yamashita H, Katai H (2010) Systemic inflammatory response in gastric cancer. World J Surg 34:2399–2400

    Article  PubMed  Google Scholar 

  4. Lukaszewicz-Zając M, Mroczko B, Gryko M, Kędra B, Szmitkowski M (2011) Comparison between clinical significance of serum proinflammatory proteins (IL-6 and CRP) and classic tumor markers (CEA and CA 19-9) in gastric cancer. Clin Exp Med 11:89–96

    Article  PubMed Central  PubMed  Google Scholar 

  5. Kao SC, Pavlakis N, Harvie R, Vardy JL, Boyer MJ, van Zandwijk N et al (2010) High blood neutrophil-to-lymphocyte ratio is an indicator of poor prognosis in malignant mesothelioma patients undergoing systemic therapy. Clin Cancer Res 16:5805–5813

    Article  CAS  PubMed  Google Scholar 

  6. Hwang JE, Kim HN, Kim DE, Choi HJ, Jung SH, Shim HJ et al (2011) Prognostic significance of a systemic inflammatory response in patients receiving first-line palliative chemotherapy for recurred or metastatic gastric cancer. BMC Cancer 11:489

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  7. Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144:646–674

    Article  CAS  PubMed  Google Scholar 

  8. Lee DY, Hong SW, Chang YG, Lee WY, Lee B (2013) Clinical significance of preoperative inflammatory parameters in gastric cancer patients. J Gastric Cancer 13(2):111–116

    Article  PubMed Central  PubMed  Google Scholar 

  9. Keizman D, Gottfried M, Ish-Shalom M, Maimon N, Peer A, Neumann A, Rosenbaum E, Kovel S, Pili R, Sinibaldi V, Carducci MA, Hammers H, Eisenberger MA, Sella A (2012) Pretreatment neutrophil-to-lymphocyte ratio in metastatic castration-resistant prostate cancer patients treated with ketoconazole: association with outcome and predictive nomogram. Oncol 17:1508–1514

    Article  CAS  Google Scholar 

  10. Kishi Y, Kopetz S, Chun YS et al (2009) Blood neutrophil to lymphocyte ratio predicts survival in patients with colorectal liver metastases treated with systemic chemotherapy. Ann Surg Oncol 16:614–622

    Article  PubMed  Google Scholar 

  11. An X, Ding PR, Li YH et al (2010) Elevated neutrophil to lymphocyte ratio predicts survival in advanced pancreatic cancer. Biomarkers 15:516–522

    Article  CAS  PubMed  Google Scholar 

  12. Cho H, Hur HW, Kim SW et al (2009) Pre-treatment neutrophil to lymphocyte ratio is elevated in epithelial ovarian cancer and predicts survival after treatment. Cancer Immunother 58:15–23

    Article  CAS  Google Scholar 

  13. Walsh SR, Cook EJ, Goulder F, Justin TA, Keeling NJ (2005) Neutrophil–lymphocyte ratio as a prognostic factor in colorectal cancer. J Surg Oncol 91:181–184

    Article  CAS  PubMed  Google Scholar 

  14. Gondo T, Nakashima J, Ohno Y et al (2012) Prognostic value of neutrophil-to-lymphocyte ratio and establishment of novel preoperative risk stratification model in bladder cancer patients treated with radical cystectomy. Urology 79:1085–1091

    Article  PubMed  Google Scholar 

  15. Bambury RM, Teo MY, Power DG, Yusuf A, Murray S, Battley JE, Drake C, O’Dea P, Bermingham N, Keohane C, Grossman SA, Moylan EJ, O’Reilly S (2013) The association of pre-treatment neutrophil to lymphocyte ratio with overall survival in patients with glioblastoma multiforme. J Neurooncol 114:149–154

    Article  CAS  PubMed  Google Scholar 

  16. Eisenhauer EA, Therasse P, Bogaerts J et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45:228–247

    Article  CAS  PubMed  Google Scholar 

  17. Danila DC, Fleisher M, Scher HI (2011) Circulating tumor cells as biomarkers in prostate cancer. Clin Cancer Res 17(12):3903–3912

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  18. Morris MJ, Autio KA, Basch EM, Danila DC, Larson S, Scher HI (2013) Monitoring the clinical outcomes in advanced prostate cancer: what imaging modalities and other markers are reliable? Semin Oncol 40(3):375–392

    Article  PubMed  Google Scholar 

  19. Jeong JH, Lim SM, Yun JY, Rhee GW, Lim JY, Cho JY et al (2012) Comparison of two inflammation-based prognostic scores in patients with unresectable advanced gastric cancer. Oncology 83:292–299

    Article  PubMed  Google Scholar 

  20. Mantovani A, Allavena P, Sica A et al (2008) Cancer-related inflammation. Nature 454:436–444

    Article  CAS  PubMed  Google Scholar 

  21. Jarnicki A, Putoczki T, Ernst M (2010) Stat3: linking inflammation to epithelial cancer more than a “gut” felling? Cell Div 5:14

    Article  PubMed Central  PubMed  Google Scholar 

  22. Yamanaka T, Matsumoto S, Teramukai S et al (2007) The baseline ratio of neutrophils to lymphocytes is associated with patient prognosis in advanced gastric cancer. Oncology 73:215–220

    Article  PubMed  Google Scholar 

  23. Keizman D, Ish-Shalom M, Huang P et al (2012) The association of pre-treatment neutrophil to lymphocyte ratio with response rate, progression free survival and overall survival of patients treated with sunitinib for metastatic renal cell carcinoma. Eur J Cancer 48:202–208

    Article  CAS  PubMed Central  PubMed  Google Scholar 

Download references

Conflict of interest

The authors of this manuscript have no conflicts of interest to disclose. The authors have full control of all the primary data and agree to allow the journal to review the data if requested.

Author information

Authors and Affiliations

  1. Tıp FakültesiTıbbiOnkoloji BD, Mustafa Kemal Üniversitesi, Hatay, Turkey

    Ahmet Taner Sümbül

  2. Tıp FakültesiTıbbiOnkoloji BD, Başkent Üniversitesi, Ankara, Turkey

    Ahmet Sezer, Hüseyin Abalı, Fatih Köse, Hüseyin Mertsoylu, Sadık Muallaoğlu & Özgür Özyılkan

  3. Tıp Fakültesi Hastanesi İç hastalıkları BD, BezmiAlem Vakıf Üniversitesi, Istanbul, Turkey

    İlhami Gültepe

Authors
  1. Ahmet Taner Sümbül
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ahmet Sezer
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Hüseyin Abalı
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Fatih Köse
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. İlhami Gültepe
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Hüseyin Mertsoylu
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Sadık Muallaoğlu
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Özgür Özyılkan
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ahmet Taner Sümbül.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Sümbül, A.T., Sezer, A., Abalı, H. et al. Neutrophil-to-lymphocyte ratio predicts PSA response, but not outcomes in patients with castration-resistant prostate cancer treated with docetaxel. Int Urol Nephrol 46, 1531–1535 (2014). https://doi.org/10.1007/s11255-014-0664-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11255-014-0664-7

Keywords

Search

Navigation